Clinical trial · Observational
QUANTACT : Impact of Pangenomic QUANTitative Alterations in Cancer Therapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
"Precision medicine and targeted therapies have played a crucial role over the past ten years in the personalized care of cancer patients. In this retrospective and observational study, we focused on patients for which no standard or curative treatment was available and for which the management was discussed in a Molecular Tumor Board (MTB). The role of the MTB is to decide the most appropriate therapeutic options for patients according to the potential identification of molecular targets. Among the analyses carried out, we focused on a quantitative genome-wide analysis: the CGH/SNP-array (Comparative Genomic Hybridization / Single Nucleotide Polymorphism on array). The objective was to evaluate the impact of CGH/SNP-array analyses in the identification of targeted molecular alterations. "
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Tumor | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Number of targeted molecular alterations
- timeFrame
- at day 0
- description
- Number of targeted molecular alterations
Secondary outcomes (1)
- measure
- Number of patients eligible for targeted therapy (clinical trials or "off-label" drug)
- timeFrame
- at day 0
- description
- Number of patients eligible for targeted therapy (clinical trials or "off-label" drug)
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Histologically or cytologically confirmed solid tumor malignancy that is advanced or metastatic ; * no standard or curative treatment available; * non-opposition of the patient collected. Exclusion Criteria: * multiple cancer patient; * ECOG Scale of Performance Status (PS) ≥2
References
Publications (0)
Data not yet available